| Trial ID: | L3572 |
| Source ID: | NCT01208701
|
| Associated Drug: |
Atorvastatin
|
| Title: |
The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy
|
| Acronym: |
STAD
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Nephropathy|Cardiovascular Diseases|Diabetes Mellitus
|
| Interventions: |
DRUG: Atorvastatin|DRUG: Unikalk
|
| Outcome Measures: |
Primary: Fractional excretion of sodium, 5 days treatment | Secondary: Systolic blood pressure, 5 days|Plasma renin concentration, 5 days|Arterial stiffness, 5 days|Plasma angiotensin II concentration, 5 days|Urinary excretion of protein from sodium channels such as the NaCl cotransporter (NCC), the Na-K-Cl cotransporter (NKCC) and the epithelial sodium channel (ENaC), 5 days|Augmentations index, 5 days
|
| Sponsor/Collaborators: |
Sponsor: Erling Bjerregaard Pedersen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
25
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2010-05
|
| Completion Date: |
2012-01
|
| Results First Posted: |
|
| Last Update Posted: |
2015-08-21
|
| Locations: |
Medicinsk Forskning, Regionshospitalet Holstebro, Holstebro, 7500, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT01208701
|
